Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.

Front Immunol · 2025 · PMC11897025 · PMID 40079007

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For patients who achieved CRc after one cycle of CACAG-VEN, MRD-negative patients showed a trend of decreased CIR compared to MRD-positive patients, albeit with non-significant statistical differences between the groups.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.